Gansevoort et al., 1992 - Google Patents
Sodium depletion enhances the antiproteinuric effect of ACE inhibition in established experimental nephrosisGansevoort et al., 1992
View PDF- Document ID
- 16772982851486716692
- Author
- Gansevoort R
- Wapstra F
- Weening J
- De Jong P
- de Zeeuw D
- Publication year
- Publication venue
- Nephron
External Links
Snippet
Dear Sir, The beneficial effect of angiotensin-I-converting-enzyme inhibition (ACEi) to prevent both a rise in proteinuria as well as progression of renal function loss has been documented in different models of experimental nephrosis [1]. Extrapolation to the human …
- 230000001597 anti-proteinuria 0 title abstract description 13
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heeg et al. | Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril | |
| US4582705A (en) | Composition for detoxification | |
| EP0555087B1 (en) | Peritoneal dialysis solutions containing at least one dipeptide | |
| Zäuner et al. | Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial | |
| JPH09512552A (en) | Methods and compositions for treating renal diseases and disorders | |
| KR930003912A (en) | Congestive Heart Failure Treatment Cure | |
| JPS58126767A (en) | Elemental diet for hepatopathic patient | |
| McLeod et al. | Urolithiasis complicating inflammatory bowel disease | |
| EA014772B1 (en) | Treatment of liver diseases in which iron plays a role in pathogenesis | |
| Bruck et al. | Hypothyroidism minimizes liver damage and improves survival in rats with thioacetamide induced fulminant hepatic failure | |
| Gansevoort et al. | Sodium depletion enhances the antiproteinuric effect of ACE inhibition in established experimental nephrosis | |
| US4902718A (en) | Calcium homeostasis compositions and methods for controlling calcium metabolism | |
| Gimenez et al. | Prevention of phosphate-induced progression of uremia in rats by 3-phosphocitric acid | |
| Vente et al. | Prospective randomized double‐blind trial of branched chain amino acid enriched versus standard parenteral nutrition solutions in traumatized and septic patients | |
| KINCAID‐SMITH et al. | Changing concepts in the management of hypertension | |
| AU2002334001B2 (en) | Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia | |
| CA2376260A1 (en) | High density lipoprotein against organ dysfunction following haemorrhagic shock | |
| Green et al. | Mechanisms of desoxycorticosterone action VII. Influence of the pituitary | |
| US6831064B1 (en) | Use of urodilatin for treating chronic kidney failure with residual kidney functions | |
| JPH04312527A (en) | Method of treating hepatic inssuficiency and liver disease | |
| Jancsó-Gábor et al. | Action of rare earth metal complexes on neurogenic as well as on bradykinin-induced inflammation | |
| Mujais | Muscle cramps during hemodialysis | |
| Kiesel et al. | Prevention of diabetes in BB rats by an E. coli extract(OM-89) | |
| CAYER | Use of Methionine and Vitamin Supplements in Treatment of Hepatic Disease: Clinical and Laboratory Observations | |
| Henry et al. | A clinical trial of cyclosporine G in cadaveric renal transplantation |